IGF-1 LR3 and mecasermin: the lab analog and the approved drug

IGF-1 and its carriers

Insulin-like growth factor 1 (IGF-1) is the main mediator of growth hormone. In blood it is almost always bound: according to the mecasermin label, more than 80% circulates in a complex with IGFBP-3 and an acid-labile subunit. That complex acts as a reservoir: IGF-1 clearance is inversely proportional to IGFBP-3 concentration¹. This biology explains both the approved drug and the lab analog now being discussed in clinic.

Mecasermin: the IGF-1 that is approved

Mecasermin (Increlex) is recombinant human IGF-1, with initial FDA approval in 2005. It is indicated for growth failure in pediatric patients aged 2 years and older with severe primary IGF-1 deficiency (height and basal IGF-1 ≤ −3.0 standard deviations with normal or elevated GH) or with GH gene deletion and neutralizing antibodies. The label states that it is not a substitute for GH and is not indicated in secondary forms of IGF-1 deficiency¹.

Efficacy evidence is solid within that indication. In 76 children with GH insensitivity treated for up to 12 years, height velocity rose from 2.8 cm/yr to 8.0 cm/yr in the first year (P < 0.0001) and stayed above baseline for up to 8 years².

What the label requires

The safety profile is known and manageable, but it demands monitoring. In that cohort, hypoglycemia (also observed before treatment) was reported in 49% of patients, injection-site lipohypertrophy in 32% and tonsillar or adenoidal hypertrophy in 22%; events rarely required stopping treatment². In the European Eu-IGFD registry (306 patients), the rate was 0.11 hypoglycemia events per patient per treatment year, and 0.01 serious events³.

The label warns of severe hypoglycemia with seizures and asks for dosing within ±20 minutes of a meal; it also describes intracranial hypertension, lymphoid tissue hypertrophy, slipped capital femoral epiphysis and scoliosis progression. It is contraindicated in active or prior malignant neoplasia: there were postmarketing reports of neoplasms whose relationship to the drug is unknown. In children with primary deficiency, the estimated terminal half-life is 5.8 hours¹.

IGF-1 LR3: engineered to escape the IGFBPs

IGF-1 LR3 (Long R3 IGF-I) was developed in Adelaide in the early 1990s. It adds the first 11 amino acids of methionyl porcine GH plus the dipeptide Val-Asn (13 residues in total) to human IGF-1 and replaces glutamic acid 3 with arginine, for 83 amino acids⁶. The result has been precisely characterized: about 1000-fold lower affinity than IGF-1 for IGFBP-3 and other IGFBPs, and 5 to 10 times greater potency in L6 myoblasts⁴.

The mechanism is not a more strongly activated receptor. In chicken embryo fibroblasts, which secrete no detectable IGFBPs, Long [Arg3]-IGF-I was less potent than IGF-1; its advantage appears only where binding proteins could sequester it⁶. The product sheet is in the catalog.

What the animal studies show

In growing female rats, 14 days of subcutaneous IGF-1 infusion were associated with greater weight gain, better nitrogen retention and better feed efficiency; the highest dose, 278 µg/day, produced 18–26% increases. With IGF-1 LR3, 44 µg/day produced similar effects. Human GH at 213 µg/day did not stimulate growth in that model⁷. In the same group's series of comparisons, the analog was about 6 times more potent than IGF-1 for growth⁴.

The potency also shows in glucose. In pigs and marmosets, the low-IGFBP-binding variants were 2 to 3 times more potent than IGF-1 at lowering blood glucose, with 4- to 8-fold greater cumulative hypoglycemia over 4 hours⁸. For a research protocol, this makes hypoglycemia the first risk to monitor in any study subject.

Half-life: shorter, not longer

It is common to read that IGF-1 LR3 has a half-life of a day or more. The published data say the opposite. In non-pregnant rats, metabolic clearance was 9.84 ml/min/kg for IGF-1 LR3 vs 0.90 ml/min/kg for IGF-1, about 11 times faster; most of the analog circulated as free peptide⁵. The authors summarize it this way: "an IGF variant which associates poorly with IGFBPs is removed more rapidly from the blood and is more potent than IGF-I"⁴.

An anti-doping study confirmed this by another route: after an intramuscular injection in rats, intact IGF-1 LR3 disappeared from blood after 4 hours, although its degradation fragments were detected up to 16 hours⁹. The prolonged effect that has been described is pharmacodynamic: sustained hypoglycemia was seen "despite their more rapid clearance from the circulation"⁸.

Its real place: the laboratory

Where IGF-1 LR3 has an established use is biotechnology. In serum-free CHO cell cultures producing recombinant proteins, it sustained viability under production conditions better than insulin, the most widely used growth factor in those media¹⁰. In humans, by contrast, there is no published trial: a French anti-doping laboratory notes that these analogs "were never approved for use in humans" and circulate on the black market with lower-quality oxidized forms⁹. In another black-market product, IGF-1 LR3 was identified carrying a histidine tag, typical of research reagents¹¹.

The honest limits: IGF-1 and cancer

IGF-1 stimulates cell proliferation, and epidemiology has studied it for two decades. A meta-analysis of 21 studies (3609 cases and 7137 controls) associated high circulating IGF-1 with more prostate cancer (OR 1.49; 95% CI 1.14–1.95) and premenopausal breast cancer (OR 1.65), associations the authors described as modest and varying by site¹². These are data on the body's own IGF-1, not on any analog; the full discussion of secretagogues is in CJC-1295, ipamorelin and MK-677.

The mecasermin label reflects the same caution: contraindication in malignant neoplasia and monitoring for new neoplasms¹. For IGF-1 LR3 there are no long-term safety data in any species that would allow that risk to be quantified.